

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
02 November 2017 (02.11.2017)



(10) International Publication Number
WO 2017/189483 A1

(51) International Patent Classification:

A61K 9/127 (2006.01) *A61P 3/10* (2006.01)
G01N 33/68 (2006.01)

(21) International Application Number:

PCT/US2017/029250

(22) International Filing Date:

25 April 2017 (25.04.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/326,871 25 April 2016 (25.04.2016) US

(71) Applicant: **THE JOHNS HOPKINS UNIVERSITY**
[US/US]; 3400 N. Charles Street, Baltimore, MD 21218
(US).

(72) Inventor: **FU, Dax**; 10 Winthrop Road, Short Hills, NJ
07078 (US).

(74) Agent: **FEULNER, Gregory**; 1812 Ashland Avenue, Suite
110, Baltimore, MD 21205 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR,
KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: ZNT8 ASSAYS FOR DRUG DEVELOPMENT AND PHARMACEUTICAL COMPOSITIONS

(57) Abstract: The present invention describes methods of identifying drugs for the treatment or prevention of diabetes by measuring the activity of the human zinc transporter ZnT8 and pharmaceutical compositions.



WO 2017/189483 A1

ZNT8 ASSAYS FOR DRUG DEVELOPMENT AND PHARMACEUTICAL
COMPOSITIONS

REFERENCE TO RELATED APPLICATIONS

5 This application claims the benefit of U.S. Provisional Patent Application No. 62/326,871, filed on April 25, 2016, both of which are hereby incorporated by reference for all purposes as if fully set forth herein.

STATEMENT OF GOVERNMENTAL INTEREST

10 This invention was made with government support under grant no. R01 GM065137-13 from the National Institutes of Health. The government has certain rights in the invention.

BACKGROUND OF THE INVENTION

The escalating type-2 diabetes (T2D) epidemic is a major global health concern.

15 Given that T2D is partly genetically determined, genetic factors that increase T2D susceptibility enhance related medical complications and lower the life spans of patients with T2D. Recent advances in genome-wide association studies (GWASs) revived the initial optimism of identifying T2D susceptibility genes and accelerated the discovery of these susceptibility gene for diabetes. Genes affecting risk for T2D have been published including

20 the zinc transporter, member 8 (SLC30A8) gene also known as ZnT8. ZnT8 is one of nine human genes of multi-spanning transmembrane proteins facilitating Zn²⁺ efflux from the cell and sequestration into intracellular compartments. Within the pancreas, specifically in the islet, there are specific zinc transporter (ZnT8) that mediates zinc enrichment in insulin

secretory granules of pancreatic beta cells. There are known variants of ZnT8 DNA and protein sequences including a nonsynonymous variant of human ZnT8 (R325W) that is thought to contribute to the susceptibility of type-2 diabetes (T2D), but it remains unclear how the risk allele correlates with zinc transport.

5

SUMMARY OF THE INVENTION

This application includes a method of identifying a drug to treat or prevent diabetes in subjects comprising the steps of: providing a proteoliposome with a zinc transporter ZnT8, or functional part thereof; administering an agent to the proteoliposome forming a treated sample; measuring the activity of the zinc transporter ZnT8 in the treated sample to obtain a first activity measurement and comparing the first activity measurement to a second activity measurement of a reference; and identifying the drug when the first activity measurement is lower than the second activity measurement. The preferred reference are proteoliposome with a ZnT8 transporter or variant thereof substantially free of agent. A suitable activity of zinc transporter ZnT8 measured in the present invention is the rate of zinc transport efficiency wherein the first measurement is from 1.3, 1.4, 1.5, 1.6, 2.0, 2.2, 2.4, 2.8, 3.0, 3.2, 3.4, 3.6, 3.8, 4.0, 4.2, 4.4, 4.6 to 5.0, 5.2, 5.4, 5.6, 5.8, 6.0, 6.2, 6.4, 6.6, 6.8, 7.0, 7.2, 7.4, 7.6, 7.8, 8.0, 9.0, 10.0, 11.0, 15.0 fold lower than the second measurement and wherein the rate of zinc transport efficiency is based on a V_{max}/K_m value using stopped-flow kinetics.

20 Another embodiment of the present invention is a method of identifying a drug to treat or prevent diabetes in subjects comprising the steps of: providing a first sample that expresses a zinc transporter ZnT8, or functional part thereof; administering an agent to the first sample forming a treated sample; measuring the activity of the zinc transporter ZnT8 in

the treated sample to obtain a first activity measurement and comparing the first activity measurement to a second activity measurement of a reference; and identifying the drug when the first activity measurement is lower than the second activity measurement. Suitable zinc transporters used in the present invention include the nonsynonymous variant of human ZnT8 (R325W) and a ZnT8 protein or peptide that has activity and is modified such as with a tag, such as a His-tag. The sample may be in vitro human cells such as HEK293 cells that stably express ZnT8 or a biological sample obtained from a subject such as a biopsy, cells, or tissue. There are alternative ways in which the activity of the zinc transporter ZnT8 is measured including measuring the intracellular zinc accumulation in the sample or the rate of zinc transport efficacy wherein the first activity measurement is from 1.3, 1.4, 1.5, 1.6, 2.0, 2.2, 2.4, 2.8, 3.0, 3.2, 3.4, 3.6, 3.8, 4.0, 4.2, 4.4, 4.6 to 5.0, 5.2, 5.4, 5.6, 5.8, 6.0, 6.2, 6.4, 6.6, 6.8, 7.0, 7.2, 7.4, 7.6, 7.8, 8.0, 9.0, 10.0, 11.0, 15.0 fold lower than the second activity measurement. Typically, the rate of zinc transport efficiency is based on a V_{max}/K_m value using stopped-flow kinetics. The agent is selected from the group comprising an antibody, portion of an antibody, nucleic acid, peptide, protein, chemical or combination thereof.

Another embodiment of the present invention is a pharmaceutical composition comprising a drug of the present invention, salt, solvate, or stereoisomer thereof. The present invention identified lipids that inhibit the activity of ZnT8, specifically lysophosphatidylcholines, cholesterol, or combinations thereof and example of a drug of the present invention.

Another embodiment of the present invention is a method of inhibiting ZnT8 activity in pancreas cells of a subject comprising administering to the subject an effective amount of the drug of the present invention, salt, solvate, or stereoisomer thereof. An additional step to

this method maybe having the ZnT8 activity measured in a sample taken from the subject before and after the subject is administered the drug by determining the rate of zinc transport efficiency in the sample. The rate of zinc transport efficiency after the subject is administered the drug is from 1.3, 1.4, 1.5, 1.6, 2.0, 2.2, 2.4, 2.8, 3.0, 3.2, 3.4, 3.6, 3.8, 4.0, 4.2, 4.4, 4.6 to 5 5.0, 5.2, 5.4, 5.6, 5.8, 6.0, 6.2, 6.4, 6.6, 6.8, 7.0, 7.2, 7.4, 7.6, 7.8, 8.0, 9.0, 10.0, 11.0, 15.0 fold lower than before the subject was administered the drug. The rate of zinc transport efficiency is preferably based on a V_{max}/K_m value using stopped-flow kinetics.

Another embodiment of the present invention is a method of treating or preventing diabetes in a subject comprising administering to the subject an effective amount of the drug 10 of the present invention, salt, solvate, or stereoisomer thereof.

Another embodiment of the present invention is a method of purifying a zinc transporter ZnT8 comprising the steps of: providing a crude preparation of a zinc transporter ZnT8 comprising proteins other than the zinc transporter ZnT8; reconstituting the crude preparation of the zinc transporter ZnT8 in a liposome forming a transporter proteoliposome 15 comprising the ZnT8 in a solution; separating the solution from the transporter proteoliposome; and forming a purified zinc transporter ZnT8. Suitable liposomes used in the present invention comprise a lipid including anionic phospholipids, non-bilayer phospholipids, cholesterol, phosphatidylinositol (PI), phosphatidylserine (PS), lysophosphatidylcholine (LPC), cholesterol, or a combination thereof. The crude preparation 20 of zinc transporter ZnT8 is reconstituted in a liposome to maintain the activity of zinc transporter ZnT8 during the separation step, such as centrifugation, for example. The method of the present invention not only creates a highly purified zinc transporter ZnT8, but a purified Zinc transporter ZnT8 having a V_{max} greater than 4, greater than 5, or greater than

6. The purified zinc transporter ZnT8 of the present invention may be in the R-conformation, the W-conformation, or a combination thereof. A crude preparation of zinc transporter ZnT8 used in the present invention may be defined as a product of affinity purification, typically where the affinity purification comprises metal affinity resins, for example. The methods of the present invention may include additional steps such as detecting anti-ZnT8 autoantibodies in a subject using the purified zinc transporter ZnT8, thereby diagnosing type-1 diabetes in a subject. The method of the present invention may generate anti-ZnT8 mAbs such as humanized anti-ZnT8 mAbs that are conformational specific, for example. Other steps include performing diagnostic beta-cell imaging using the antibodies of the present invention or creating a mAb-based therapeutic ZnT8 inhibitors using the antibodies of the present invention.

The term "activity" refers to the ability of a gene to perform its function such as ZnT8 (a zinc transporter) being able to transport zinc.

The term "express" refers to the ability of a gene to express the gene product including for example its corresponding mRNA or protein sequence (s).

The term "reference" refers to a standard or control conditions such as a sample (human cells) or preteoliposomes with a zinc transporter ZnT8 free, or substantially free, of agent.

The term "subject" refers to any individual or patient to which the method described herein is performed. Generally the subject is human, although as will be appreciated by those in the art, the subject may be an animal. Thus other animals, including mammals such as rodents (including mice, rats, hamsters and guinea pigs), cats, dogs, rabbits, farm animals including cows, horses, goats, sheep, pigs, etc., and

primates (including monkeys, chimpanzees, orangutans and gorillas) are included within the definition of subject.

The term “ZnT8” is intended to refer to the (SLC30A8) gene and variants as well as products including nucleic acid and protein sequences derived therefrom. ZnT8 includes
5 modified nucleic acid and amino acid sequences including tags for visualization for example. Examples of ZnT8 nucleic acid and protein sequences suitable for the present invention include: Homo sapiens clone SLC30A8 DNA sequence having a NCBI Accession Number KR712225.1 and Homo sapiens SLC30A8 protein sequence having a NCBI Accession
10 Number ABQ59023.1 as examples. An example of a ZnT8 gene sequence is SLC30A8 solute carrier family 30 member 8 [Homo sapiens (human)] having an NCBI Gene ID: 169026. The ZnT8 used in the present invention may be eukaryotic including human and animal or prokaryotic including bacterial ZnT8 transporters.

BRIEF DESCRIPTION OF THE DRAWINGS

15 Figure 1A-1D illustrates the induced expression and characterization of human ZnT8 variants. Fig. 1A illustrates Western blotting analysis of inducible expression of ZnT8 variants. Fig. 1B illustrates intracellular localization of ZnT8 expression by immunofluorescence. Fig. 1C illustrates imaging of intracellular zinc accumulation. Fig 1D illustrates the time course of zinc accumulation.

20 Figure 2A-2C illustrates the purification of human ZnT8 variants. Fig. 2A illustrates a homology model of human ZnT8. Fig. 2B illustrates the purification and reconstitution of ZnT8 variants. Fig. 2C illustrates the sizing of HPLC profiles of the purified ZnT8.

Figure 3A-3B illustrates the kinetic analysis of ZnT8 variants. Fig. 3A illustrates the fluorescence responses to increasing zinc concentrations. Fig. 3B illustrates the steady state kinetics.

Figure 4 illustrates the functional regulation of ZnT8 by lipids.

5 Figure 5 illustrates the time courses of Zimpry-1 fluorescence in response to the addition of zinc at 0, 5, 19 or 283 nM. The fluorescence response were measured in stable expression HEK293 cells with or without induction of the R and W form as indicated. Blk is a negative control using parental HEK293 cells with no ZnT8 over-expression.

Figure 6 illustrates steady state kinetics of the R and W form in reconstituted
10 proteoliposomes with defined compositions as indicated.

DETAILED DESCRIPTION OF THE INVENTION

The islet-specific zinc transporter ZnT8 mediates zinc enrichment in insulin secretory granules of pancreatic beta cells. A nonsynonymous variant of human ZnT8 (R325W)
15 contributes to the susceptibility of type-2 diabetes (T2D), but it remains unclear how the risk allele correlates with zinc transport. Here we report a comparative analysis of a pair of high-risk (R325) and low-risk (W325) variant. The R-form was found hyperactive following induced expression in HEK293 cells. Reconstitution of purified R-form into biomimetic membranes yielded a 51% increase in the transport rate. During insulin granule biogenesis,
20 the hosting membrane of ZnT8 undergoes enormous lipid remodeling. ZnT8 variants were shown functionally tunable to stimulation by anionic phospholipids and inhibition by cholesterol and non-bilayer phospholipids. Over a broad range of permissive lipid compositions, the R-form consistently exhibited accelerated zinc transport kinetics, indicating

that the high-risk variant may be targeted for inhibition to reduce T2D risk in the general population.

Zinc forms stable complexes with insulin hexamers, enabling crystalline packing of
5 the secretory granules of pancreatic beta cells. Defective insulin secretion in the face of
insulin resistance is a main physiological characteristic of T2D, a complex multifactorial
polygenetic disease with more than 80 T2D-susceptibility loci/genes identified so far by
genome-wide association studies (GWASs). A nonsynonymous single nucleotide
polymorphism in *SLC30A8* (rs13266634 C>T), which causes an arginine to tryptophan
10 change at position 325 (R325W), is associated with a 53% increased risk of developing T2D (Sladek R, Rocheleau G, Rung J, Dina C, Shen L, Serre D, Boutin P, Vincent D, Belisle A, Hadjadj S, *et al.* (2007) *Nature*. 445, 881-885.). The risk allele is widespread in more than
50% of the population according to HapMap data (build 35). *SLC30A8* encodes a granular
zinc transporter known as ZnT8. In pancreatic beta cells, ZnT8 is highly expressed and
15 responsible for transporting cytosolic zinc into insulin granules. However, the molecular
mechanism underlying the genetic susceptibility of *ZnT8* polymorphisms remains
controversial. ZnT8 inactivation in various mouse models revealed large phenotypic
variations ranging from decreased, unchanged to even enhanced insulin secretion. Over-
expression and functional characterization of polymorphic alleles in pancreatic beta cells
20 suggested an attenuated zinc transport activity associated with an increased T2D
susceptibility, whereas genotyping rare nonsense and frameshift mutations of *ZnT8* in
humans indicated an opposite causal relationship, suggesting that a loss of function of ZnT8
actually reduced T2D risk. The conflicting results concerning the directional relationship

between ZnT8 activity and T2D susceptibility prevent the identification of specific defects in the risk variant for pharmacological correcting. At present, it is not clear whether stimulation or inhibition of ZnT8 might be a therapeutic option to reduce T2D risk in the general population.

5 Studies of the functional effects of GWAS-identified risk variants in humans are challenged by small effect sizes that in general do not provide a clinically useful predictor for disease risk. Although protective effects on T2D risk were observed in loss-of-function ZnT8 mutants at an occurrence rate of about 350 carriers out of ~150,000 genotyped individuals, the extrapolation of the casual relationship obtained from rare penetrant mutants to common, 10 yet mild ZnT8 polymorphic variants is not straightforward, because in humans the relationship between ZnT8 activity and diabetes risk could follow a complex bell-shaped dose-response. To determine the functional effects of the common ZnT8 polymorphic variants on T2D risk, we developed induced expression of human ZnT8 variants in HEK293 cells, purified both the R- and W-form in a native state, and achieved reconstitution in 15 biomimetic membranes with defined lipid compositions. A direct functional comparison of human ZnT8 polymorphic variants at the molecular level sidestepped inherent limitations to phenotypic interpretation of animal models. Our experiments demonstrated a clear causality between elevated zinc transport activity and increased T2D risk.

Induced expression and characterization of human ZnT8 variants. In human pancreatic islets, 20 ZnT8 expression is confined intracellularly to the beta cells and alpha cells to a lesser extent. To produce recombinant human ZnT8 variants, we generated a series of stable HEK293 cell lines, each with an isogenic integration of a His-tagged ZnT8 variant under a tetracycline-

inducible promoter. Western blotting using an antibody to the His-tag showed that the induced R- or W-form reached a similar level of expression while the uninduced basal level was suppressed below the detection limit (Fig. 1A). A two-fold increase of post-induction expression level was observed for a ZnT8 mutant (termed the AA-form) containing a double
5 Ala-substitution to the predicted transport-site. ZnT8 variants were also monitored for induced expression in HEK293 cells by immunofluorescence labeling and confocal microscopy. Post-induction immunoreactivities toward the His-tag were found predominantly restricted to the cytoplasm (Fig. 1B). Additional strong immunostaining of the nuclear envelope was observed due to non-specific antibody binding as shown by the same staining
10 pattern in uninduced cells and in HEK293 cells with no genomic *ZnT8* integration as a negative control. This cell line is referred to hereafter as blank (Blk). The effects of ZnT8 over-expression on intracellular labile zinc concentrations were examined using a membrane-permeable zinc-selective fluorescent indicator, Zinpyr-1. Zinpyr-1 labeling produced bright punctate staining in the juxtannuclear region (Fig. 1C), consistent with the trapping of Zinpyr-
15 1 in the Golgi and acidic subcellular compartments. Cells with induced expression of the R-form exhibited stronger Zinpyr-1 staining than the W- and AA-form. The basal level of Zinpyr-1 fluorescence in Blk was significant, at a level similar to that of the W- and AA-form (Fig. 1C). Quantification of Zinpyr-1 fluorescence in ~13,000 live cells by flow cytometry yielded a mean fluorescence intensity of 2860.3 ± 9.6 for the R-form and 2135.4 ± 7.6 for the
20 W-form, respectively. This result supported a higher level of vesicular zinc accumulation by induced expression of the R-form. We next monitored ZnT8-mediated vesicular zinc accumulation in real time. Stable expression cells or Blk in a 96-well microplate were loaded with Zinpyr-1, and then exposed to a zinc uptake buffer containing 1 μ M pyriothione, a zinc

ionophore that was used to break down the surface membrane barrier to zinc diffusion, enabling direct manipulation of the cytosolic free zinc concentration. Zinc exposure at 15 °C triggered a linear rise of Zinpyr-1 fluorescence within 10 min, which could be quenched by a zinc chelator TPEN. The net fluorescence difference between induced and uninduced cells
5 reflected ZnT8-mediated vesicular zinc accumulation (Fig. 1D). The rate of zinc uptake increased progressively with an increasing free zinc concentration from 5 nM to 383 nM. At lower zinc concentrations (5 and 19 nM), the rate of three ZnT8 variants showed no significant difference at a level similar to that of Blk. However, at 383 nM, the R-form exhibited a significantly faster rate of zinc accumulation than the W-form, indicating that the
10 R-form was hyperactive with respect to the W-form. The rates of the W- and AA-form were significantly faster than the basal level of Blk, suggesting that both variants were active. At 383 nM, the rank order of zinc transport activity was R>W>AA>Blk following induced expression in HEK293 cells (Fig. 1D).

Purification and reconstitution of ZnT8 variants. Significant vesicular zinc accumulation
15 observed in Blk (Fig. 5) was attributed to endogenous zinc transport activities of a multitude of zinc efflux and uptake transporters. The high background fluorescence signal, and a lack of a precise control over subcellular loading of the zinc indicator limited the potential for a quantitative comparison of ZnT8 variants. To directly compare zinc transport activities and determine which step(s) in the transport reaction cycle might be affected by the risk allele, we
20 set out to purify ZnT8 variants and to develop functional reconstitution for in-depth kinetic analysis. Homology modeling of human ZnT8 based on the crystal structure of the bacterial zinc transporter YiiP suggested that ZnT8 forms a unique Y-shaped homodimer in which two transmembrane domains (TMDs) splay out in the membrane (Fig. 2A). Lipid molecules are

expected to play an essential stabilizing role by filling the void space between two TMDs. Accordingly, we minimized ZnT8 delipidation in the purification process by coupling affinity purification to liposome reconstitution. The proteins eluted from metal affinity resins contained a major ZnT8 species as shown by SDS-PAGE (Fig. 2B). Most protein
5 contaminants were not reconstituted, thus could be separated from reconstituted ZnT8 in proteoliposomes by ultracentrifugation. Re-solubilization of proteoliposomes yielded a mostly pure protein species with slightly reduced mobility on SDS-PAGE (Fig. 2B). The molecular identities of protein bands before and after reconstitution were confirmed by western blotting using antibodies to a N-terminal epitope in ZnT8 and the C-terminal His-tag,
10 respectively (Fig. 2B).

The purified ZnT8 variants were further assessed for protein folding by size-exclusion HPLC analysis. Despite having a predicted molar absorptivity of $41535 \text{ M}^{-1}\text{cm}^{-1}$, the purified ZnT8 was nearly UV silent, probably due to the high lipid content in the detergent micelles. To detect ZnT8 elution, we labeled the purified sample with a thiol-specific fluorescent
15 probe, fluorescein-5-maleimide, and then monitored labeled-ZnT8 by fluorescent and UV detection in tandem. Size-exclusion HPLC analysis of DDM-solubilized proteoliposomes revealed a single fluorescent peak. SDS-PAGE analysis of the peak fraction with coomassie stain confirmed the presence of purified ZnT8 (Fig. 2B). HPLC re-run of the peak fraction yielded single, mono-dispersed peaks by both fluorescent and UV detections (Fig. 2C). The
20 apparent molecular weight of the purified ZnT8 was estimated to be ~120 kDa, in agreement with a dimeric assembly of two 36.5 kDa monomers with bound lipids and detergents. Compared with GFP-tagged ZnT8 in detergent crude extract, the purified ZnT8 without a GFP-tag was slightly right-shifted as a result of protein size difference (Fig. 2C). The peak

profile, however, remained essentially unchanged between the purified ZnT8 and unpurified ZnT8-GFP, indicating that ZnT8 retained a native fold after purification, reconstitution and re-solubilization. For clarity, only the HPLC chromatogram of the R-form is shown, as the profiles of the W- and AA-form were essentially identical.

- 5 Kinetic difference of ZnT8 variants in reconstituted biomimetic membranes. Zinc transport by ZnT8 is thought to be a two-step process, initiated by zinc binding to a transport-site followed by a protein conformational change that moves the bound zinc ion across the membrane barrier. This kinetic process was characterized for bacterial zinc transporters in reconstituted proteoliposomes (Chao Y & Fu D (2004) *J Biol Chem* 279, 12043-12050).
- 10 However, reconstitution of human ZnT8 variants either caused large vesicle leakage when *E. coli* polar lipid extract was used, or yielded no detectable transport activity when bovine liver polar lipid extract was used. To achieve low background leakage and high transport activity, we used a mix of synthetic Dioleoylphosphatidyl-Choline (DOPC), 1,2-di-(9Z-octadecenoyl)-*sn*-glycero-3-phosphoethanolamine (DOPE), 1,2-dioleoyl-*sn*-glycero-3-phospho-L-serine (DOPS) and pure soy phosphatidylinositol (PI) at a ratio (45:20:23:12) that
- 15 mimicked the phospholipid composition of insulin secretory granules of rat pancreatic beta cells (INS-1 832/13 cells). ZnT8-mediated zinc transport was monitored by FluoZin-3, a membrane impermeant fluorescent zinc indicator encapsulated in proteoliposomes. ZnT8-mediated zinc influx was about 5- 10 fold higher than the background leakage measured in
- 20 liposomes that were prepared without protein incorporation (Fig. 3A). The R- or W-form responded to an increasing extravesicular zinc concentration with a hyperbolic increase of the initial rate of FluoZin-3 fluorescence change (Fig. 3A). Least squares fitting of the steady-state kinetics to Michaelis–Menten equation indicated that the rate of zinc transport (V_{max})

for the high-risk R-form was 51% faster, accompanied by a small decrease of K_m (Fig. 3B, Table-1). The V_{max}/K_m value of the R-form, which is a measure of zinc transport efficacy, was 2.4 fold higher as compared to that of the W-form.

The site of R-to-W substitution in human ZnT8 is predicted to be in the vicinity of a
5 cytosolic zinc-binding site in CTD (Fig. 2A). This site is more than 50 angstroms away from
the zinc transport-site in TMD. Mutating the cytosolic zinc-binding site of YiiP was found to
impair a CTD conformational change, leading to an allosteric down-regulation of the zinc
transport activity (17). The increased zinc transport activity of the high-risk R-form is
consistent with a functional enhancement via allosteric over-stimulation. By comparison, the
10 double Ala-substitution to the transport-site in TMD is predicted to impact zinc transport
directly, in agreement with a 24-fold K_m increase and 59-fold V_{max}/K_m decrease as
compared to the corresponding kinetic parameters of the R-form. Previous work showed that
Ala-substitution of highly conserved zinc binding residues abolished transport activity of a
homologous human ZnT5 and a bacterial YiiP. Although the AA-form apparently remained
15 functional at a reduced level, the initial rate of zinc transport seemed linear with a zinc
concentration up to 1.5 mM (Fig. 3B), suggesting a possible nonspecific zinc leakage when
the specific transport-site was disrupted by a targeted mutation. Thus, the V_{max} value of the
AA-form ($0.028 \pm 0.008 \text{ s}^{-1}$) defined an upper bound non-specific leakage contributing to the
kinetic measurement of human ZnT8 variants in reconstituted proteoliposomes.

20 Functional modulation of human ZnT8 variants by lipids. During replenishment of insulin
granules following glucose stimulated insulin secretion, ZnT8 is trafficked with insulin
granule biogenesis *en route* from the endoplasmic reticulum through Golgi networks to

insulin secretory granules. The intracellular trafficking process exposes ZnT8 to a dynamic lipid composition as the membranes undergo curvature formation, granule budding and exocytotic fusion. The remodeling of insulin granule membranes results in enrichments of anionic phosphatidylinositol (PI), phosphatidylserine (PS), non-bilayer

5 lysophosphatidylcholine (LPC) and cholesterol. We further investigated the functional difference between ZnT8 variants under the influence of three major classes of lipids in insulin granules: anionic phospholipids, non-bilayer phospholipids and cholesterol. In almost all mammalian cells, PC accounts for 50% of total cellular phospholipids. PE is the second most abundant phospholipid in mammalian membranes, contributing 20–30% of total

10 phospholipid content. We therefore used a 2:1 mixture of DOPC and DOPE to form a minimal biomimetic membrane and then examined the effect of adding a third anionic phospholipid. The efficiencies of ZnT8 reconstitution for both variants as well as FluoZin-3 vesicular encapsulation remained approximately the same for the following lipid compositions, DOPC:DOPE (2:1), DOPC:DOPE:DOPG (2:1:1), DOPC:DOPE:DOPS (2:1:1)

15 and DOPC:DOPE:soyPI (2:1:1). The zinc transport activities of both variants in the DOPC:DOPE (2:1) proteoliposomes were severely reduced below the V_{max} level of the AA-form at $2.8 \times 10^{-2} \text{ s}^{-1}$ (Fig. 4). DOPG, DOPS or soyPI increased V_{max} by 6.1, 3.5 or 2.7 fold for the R-form, and 2.0, 2.3, or 2.3 fold for the W-form (Tabel-1). All three anionic phospholipids, regardless of the exact chemical nature of the headgroup, activated zinc

20 transport. Of note, the V_{max} values of the R-form were consistently larger than the W-form under all conditions of anionic lipid stimulation (Fig. 4). The zinc transport-site in the homolog model is situated in the outer leaflet of the lipid bilayer and partially accessible to interactions with surrounding lipid headgroups (Fig. 2A). DOPS and soyPI, both abundantly

found in the insulin granule membranes, seemed to facilitate zinc binding as suggested by a modest decrease of K_m values (Table 1). DOPG is not a native anionic lipid in insulin granules with slightly increased K_m values for both the R- and W-form.

Table 1, Summary of kinetic parameters

ZnT8 Variant	R325		W325	
Lipid compositions	V_{max} ($0.01s^{-1}$)	K_m (\square)	V_{max} ($0.01s^{-1}$)	K_m (\square)
DOPC:DOPE:DOPS:soyPI (45:20:23:12)	6.22±0.38	103.1±22. 2	4.07±0.1 9	162.2±24. 4
DOPC:DOPE (2:1)	2.00±0.22	205.4±70. 0	2.15±0.1 5	169.2±36. 8
DOPC:DOPE:DOPG (2:1:1)	12.10±0.3	252.9±18. 8	4.22±0.2 2	218.4±40. 0
DOPC:DOPE:DOPS (2:1:1)	6.99±0.28	165.5±21. 1	4.97±0.2 6	159.2±30. 0
DOPC:DOPE:soyPI (2:1:1)	5.39±0.21	131.0±17. 7	4.95±0.1 6	125.2±14. 3
DOPC:DOPE:DOPS:LPC (1:1:1:1)	1.69±0.17	33.0±17.0	2.47±0.1 8	52.3±16.4
DOPC:DOPE:DOPG (1:1:1)	10.39±0.5	259.7±36. 3	6.39±0.4 7	219.3±46. 8
DOPC:DOPE:DOPG (1:2:1)	6.39±0.16	418.2±25. 4	4.36±0.2 2	416.5±44. 9
DOPC:DOPE:DOPS:soyPI+SM (45:20:23:12+10 mol%)	5.84±0.37	125.6±25. 2	3.73±0.2 4	104.8±24. 3
DOPC:DOPE:DOPG+cholesterol (2:1:1+10 mol%)	2.57±0.32	134.0±56. 1	2.59±0.2 4	160.3±47. 3

DOPC:DOPE:DOPS+cholesterol (2:1:1+10 mol%)	ND	ND	ND	ND
DOPC:DOPE:LPC:DOPS+cholesterol (1:1:1:1+10 mol%)	ND	ND	ND	ND

Next we examined the effects of two non-bilayer phospholipids, namely the invert conical LPC and conical DOPE. These non-cylindrical phospholipids alone do not form lipid bilayers, but can be stabilized in the bilayer structure by the presence of 20-50% cylindrical phospholipids (DOPC, DOPS and DOPG). Adding LPC to 25% or increasing the DOPE concentration in reconstitution mixture did not affect the efficacies of ZnT8 insertion and Fuzin-3 encapsulation, but background zinc leakage slightly increased due to increased bilayer deformation. LPC (Lysophosphatidylcholine, lysoPC) in reconstituted DOPC:DOPE:DOPS:LPC (1:1:1:1) proteoliposomes reduced the V_{max} value of both ZnT8 variants below the reference level of the AA-form (Fig. 4). Interestingly, LPC also significantly reduced the K_m values of both ZnT8 variants (Tabel-1). The apparent tightening of zinc binding seemed to impede the transmembrane crossing of bound zinc, resulting in a marked decrease of V_{max} for both ZnT8 variants. LPC is highly enriched in insulin granules, accounting for 20% of total granule lipids. When inserted into the lipid bilayer, the cone-shaped LPC introduced positive curvature, and the ensuing redistribution of the bilayer lateral pressure might in turn inhibited ZnT8. In contrast, DOPE in the lipid bilayer promoted negative curvature, and increasing the concentration of DOPE in DOPC:DOPE:DOPG proteoliposomes from a ratio of 2:1:1 to 1:1:1 and 1:2:1 had modest effects on the W-form, but progressively reduced the V_{max} of the R-form. Our experiments suggested that

significant bilayer curvature changes, either in a positive or negative direction, inhibited zinc transport activity to various degrees.

The third highly enriched lipid class in insulin granule is cholesterol. The compact and conical cholesterol molecules can fit into the void space between fatty acid chains, increasing packing density and bending rigidity of the lipid bilayer. A cholesterol composition probably in the range of 40-50 mol% is required for normal insulin secretion. Many residential proteins in the insulin granule have high affinity to cholesterol, likely lowering the actual cholesterol level in the granular membrane. To examine the effect of cholesterol on ZnT8 transport activity, we added 10 mol% cholesterol to proteoliposomes made with DOPC:DOPE:DOPG (2:1:1), DOPC:DOPE:DOPS (2:1:1) or DOPE:DOPC:LPC:DOPS (1:1:1:1). The incorporation of cholesterol into proteoliposomes did not affect ZnT8 reconstitution and Fuzin-3 encapsulation, but invariably reduced the transport activities of both ZnT8 variants below the reference level of the AA-form (Tabel-1). The inhibitory effect of cholesterol explained a complete loss of ZnT8 transport activity in bovine liver polar lipid extract that contained 10 mol% cholesterol.

Recent human population genetics has identified rare loss-of-function ZnT8 variants that confer strong protective effects against T2D. This discovery validated human ZnT8 as an antidiabetic drug target. The actual target of therapeutic interventions is the common R325 risk allele in the general population. The translation of rare loss-of-function alleles to therapeutic inhibition of the common risk variant is questioned by the possibility of a bell-shaped relationship between ZnT8 activity and T2D risk. In this work, we developed quantitative analysis of human ZnT8 variants and characterized regulatory effects of major

lipid components found in insulin secretory granules. Our experiments showed that the transport activity of human ZnT8 is sensitive to functional modulations by three classes of lipids rich in insulin secretory granules: the anionic lipids activate whereas LPC and cholesterol strongly inhibit both ZnT8 variants. The high-risk R325 variant is consistently
5 more active than the low-risk W325 variant under all experimental conditions favoring transport competence (Fig. 4). The observed hyperactivity of the high-risk R325 variant mirrors a causal relationship of loss-of-function human mutants to lower T2D risk. Our results suggest that ZnT8 activity is linearly correlated with T2D risk from a mild ZnT8 polymorphic variant to penetrant loss-of-function mutants. The association of the human
10 high-risk R325 variant with ZnT8 hyperactivity suggests that the over-stimulated R325 variant may be targeted for inhibition to reduce T2D risk in the general population.

Kinetic analysis of human ZnT8 variants in various biomimetic membranes of defined lipid compositions provides insights into functional dynamics of human ZnT8 in pancreatic beta cells. The inhibitory LPC and cholesterol are both non-bilayer lipids. Their actual
15 concentrations in the insulin granule membrane are highly dynamic, depending on the partitioning between residential lipid-binding proteins and the granular membrane. Rapid turnover of the secretory pathway is a basic functional requirement for pancreatic beta cells to maintain homeostatic abundance of insulin granules. During this process, ZnT8 is trafficked with insulin granule biogenesis, thus encounters drastically different lipid compositions from
20 ER to matured insulin secretory granules. ZnT8 is commonly assumed to pump cytosolic zinc into insulin granules against a steep concentration gradient. However, the abundant presence of strong inhibitory lipids in insulin granules argues for a functional down-regulation of granular ZnT8. Secretory granules store an exceptionally high level of zinc in 10 to 30 mM

range, while the free zinc concentration in the cytoplasm is kept around a homeostatic set point below nM. The inactivation of granular ZnT8 may help reducing zinc backflow out of the zinc-enriched granules. The lipid compositions in the early secretory pathway seem more permissive for ZnT8-mediated zinc accumulation. Proinsulin is synthesized in ER and
5 loaded with zinc during the transit from ER to cis-Golgi networks. Sorting zinc-bound (pro)insulin into secretory granules could be an alternative mechanism of granular zinc enrichment if ZnT8 is indeed inhibited in the late secretory pathway. Functional studies of ZnT8 in live beta cells still await enabling technologies to track spatiotemporal dynamics of lipid compositions, subcellular ZnT8 localization and zinc concentrations at the same time.

10 Embodiments of the disclosure concern methods and/or compositions for treating and/or preventing diabetes including Type-1 or Type-2 diabetes. In certain embodiments, the level to which a drug inhibits ZnT8 activity or expression may be any level so long as it provides amelioration of at least one symptom of diabetes. The level of ZnT8 activity may decrease by at least 2, 3, 4, 5, 10, 25, 50, 100, 1000, or more fold expression compared to the
15 level of a reference, in at least some cases. An individual may monitor ZnT8 expression/activity using standard methods in the art, such as northern assays or quantitative PCR, for example.

 An individual known to have diabetes, suspected of having diabetes, or at risk for having diabetes may be provided an effective amount of an inhibitor of ZnT8 activity and/or
20 expression, including lipids. Those at risk for diabetes may be those individuals having one or more genetic factors, may be of advancing age, and/or may have a family history, for example.

In particular embodiments of the disclosure, an individual is given an agent for diabetes therapy in addition to the one or more inhibitors of ZnT8. Such additional therapy may include pharmaceutical agents that are commercially available, for example. When combination therapy is employed with one or more inhibitors of ZnT8, the additional therapy
5 may be given prior to, at the same time as, and/or subsequent to the inducer of ZnT8.

Certain methods of the disclosure provide for methods of diagnosing diabetes prior to the therapeutic methods of the disclosure, and such diagnosis may occur by any methods or means, including at least genetic marker assay.

10 Pharmaceutical Preparations. Pharmaceutical compositions of the present invention comprise an effective amount of one or more inhibitors of ZnT8 such as lysophosphatidylcholine, dissolved or dispersed in a pharmaceutically acceptable carrier. The phrases "pharmaceutical or pharmacologically acceptable" refers to molecular entities and compositions that do not produce an adverse, allergic or other untoward reaction when administered to an animal, such
15 as, for example, a human, as appropriate. The preparation of a pharmaceutical composition that comprises at least one inhibitor of expression and/or activity of ZnT8 or additional active ingredient will be known to those of skill in the art in light of the present disclosure, as exemplified by Remington: The Science and Practice of Pharmacy, 21st Ed. Lippincott Williams and Wilkins, 2005, incorporated herein by reference. Moreover, for animal (*e.g.*,
20 human) administration, it will be understood that preparations should meet sterility, pyrogenicity, general safety and purity standards as required by FDA Office of Biological Standards.

As used herein, "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, surfactants, antioxidants, preservatives (*e.g.*, antibacterial agents, antifungal agents), isotonic agents, absorption delaying agents, salts, preservatives, drugs, drug stabilizers, gels, binders, excipients, disintegration agents, lubricants, sweetening agents, 5 flavoring agents, dyes, such like materials and combinations thereof, as would be known to one of ordinary skill in the art (see, for example, Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, pp. 1289-1329, incorporated herein by reference).

Except insofar as any conventional carrier is incompatible with the active ingredient, its use in the pharmaceutical compositions is contemplated.

10 The inhibitor of the activity and/or expression of ZnT8 may comprise different types of carriers depending on whether it is to be administered in solid, liquid or aerosol form, and whether it need to be sterile for such routes of administration as injection. The present compositions can be administered intravenously, intradermally, transdermally, intrathecally, intraarterially, intraperitoneally, intranasally, intravaginally, intrarectally, topically, 15 intramuscularly, subcutaneously, mucosally, orally, topically, locally, inhalation (*e.g.*, aerosol inhalation), injection, infusion, continuous infusion, localized perfusion bathing target cells directly, *via* a catheter, *via* a lavage, in cremes, in lipid compositions (*e.g.*, liposomes), or by other method or any combination of the forgoing as would be known to one of ordinary skill in the art.

20 The inhibitor of activity and/or expression of ZnT8 (including lysophosphatidylcholine) may be provided to the individual in need thereof by dietary ingesting one or more comestibles that comprise the inhibitor, such as herbs, berries, and/or fruits.

The inhibitor of the activity and or expression of ZnT8 may be formulated into a composition in a free base, neutral or salt form. Pharmaceutically acceptable salts, include the acid addition salts, *e.g.*, those formed with the free amino groups of a proteinaceous composition, or which are formed with inorganic acids such as for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric or mandelic acid. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as for example, sodium, potassium, ammonium, calcium or ferric hydroxides; or such organic bases as isopropylamine, trimethylamine, histidine or procaine. Upon formulation, solutions will be administered in a manner compatible with the dosage formulation and in such amount as is therapeutically effective. The formulations are easily administered in a variety of dosage forms such as formulated for parenteral administrations such as injectable solutions, or aerosols for delivery to the lungs, or formulated for alimentary administrations such as drug release capsules and the like.

Further in accordance with the present disclosure, the composition of the present invention suitable for administration is provided in a pharmaceutically acceptable carrier with or without an inert diluent. The carrier should be assimilable and includes liquid, semi-solid, *i.e.*, pastes, or solid carriers. Except insofar as any conventional media, agent, diluent or carrier is detrimental to the recipient or to the therapeutic effectiveness of a composition contained therein, its use in administrable composition for use in practicing the methods of the present invention is appropriate. Examples of carriers or diluents include fats, oils, water, saline solutions, lipids, liposomes, resins, binders, fillers and the like, or combinations thereof. The composition may also comprise various antioxidants to retard oxidation of one or more component. Additionally, the prevention of the action of microorganisms can be

brought about by preservatives such as various antibacterial and antifungal agents, including but not limited to parabens (e.g., methylparabens, propylparabens), chlorobutanol, phenol, sorbic acid, thimerosal or combinations thereof.

In accordance with the present invention, the composition is combined with the carrier in any
5 convenient and practical manner, *i.e.*, by solution, suspension, emulsification, admixture, encapsulation, absorption and the like. Such procedures are routine for those skilled in the art.

In a specific embodiment of the present invention, the composition is combined or mixed thoroughly with cells of the pancreas, or other mammalian cells such as human cells,
10 for example. The mixing can be carried out in any convenient manner such as grinding. Stabilizing agents can be also added in the mixing process in order to protect the composition from loss of therapeutic activity, *i.e.*, denaturation in the stomach. Examples of stabilizers for use in an the composition include buffers, amino acids such as glycine and lysine, carbohydrates such as dextrose, mannose, galactose, fructose, lactose, sucrose, maltose,
15 sorbitol, mannitol, *etc.*

In further embodiments, the present invention may concern the use of a pharmaceutical lipid vehicle compositions that include inhibition of activity and/or expression of ZnT8, one or more lipids, and an aqueous solvent. As used herein, the term “lipid” will be defined to include any of a broad range of substances that is characteristically
20 insoluble in water and extractable with an organic solvent. This broad class of compounds are well known to those of skill in the art, and as the term “lipid” is used herein, it is not limited to any particular structure. Examples include compounds which contain long-chain aliphatic hydrocarbons and their derivatives. A lipid may be naturally occurring or synthetic

(*i.e.*, designed or produced by man). However, a lipid is usually a biological substance.

Biological lipids are well known in the art, and include for example, neutral fats, phospholipids, phosphoglycerides, steroids, terpenes, lysolipids, glycosphingolipids, glycolipids, sulphatides, lipids with ether and ester-linked fatty acids and polymerizable

5 lipids, and combinations thereof. Of course, compounds other than those specifically described herein that are understood by one of skill in the art as lipids are also encompassed by the compositions and methods of the present invention.

One of ordinary skilled in the art would be familiar with the range of techniques that can be employed for dispersing a composition in a lipid vehicle. For example, the inhibitor of
10 activity or expression of ZnT8 may be dispersed in a solution containing a lipid, dissolved with a lipid, emulsified with a lipid, mixed with a lipid, combined with a lipid, covalently bonded to a lipid, contained as a suspension in a lipid, contained or complexed with a micelle or liposome, or otherwise associated with a lipid or lipid structure by any means known to those of ordinary skill in the art. The dispersion may or may not result in the formation of
15 liposomes.

The actual dosage amount of a composition of the present invention administered to an animal patient can be determined by physical and physiological factors such as body weight, severity of condition, the type of disease being treated, previous or concurrent therapeutic interventions, idiopathy of the patient and on the route of administration.

20 Depending upon the dosage and the route of administration, the number of administrations of a preferred dosage and/or an effective amount may vary according to the response of the subject. The practitioner responsible for administration will, in any event, determine the

concentration of active ingredient(s) in a composition and appropriate dose(s) for the individual subject.

In certain embodiments, pharmaceutical compositions may comprise, for example, at least about 0.1% of an active compound. In other embodiments, the an active compound may
5 comprise between about 2% to about 75% of the weight of the unit, or between about 25% to about 60%, for example, and any range derivable therein. Naturally, the amount of active compound(s) in each therapeutically useful composition may be prepared in such a way that a suitable dosage will be obtained in any given unit dose of the compound. Factors such as solubility, bioavailability, biological half-life, route of administration, product shelf life, as
10 well as other pharmacological considerations will be contemplated by one skilled in the art of preparing such pharmaceutical formulations, and as such, a variety of dosages and treatment regimens may be desirable.

In other non-limiting examples, a dose may also comprise from about 1 microgram/kg/body weight, about 5 microgram/kg/body weight, about 10
15 microgram/kg/body weight, about 50 microgram/kg/body weight, about 100 microgram/kg/body weight, about 200 microgram/kg/body weight, about 350 microgram/kg/body weight, about 500 microgram/kg/body weight, about 1 milligram/kg/body weight, about 5 milligram/kg/body weight, about 10 milligram/kg/body weight, about 50 milligram/kg/body weight, about 100 milligram/kg/body weight, about 200
20 milligram/kg/body weight, about 350 milligram/kg/body weight, about 500 milligram/kg/body weight, to about 1000 mg/kg/body weight or more per administration, and any range derivable therein. In non-limiting examples of a derivable range from the numbers listed herein, a range of about 5 mg/kg/body weight to about 100 mg/kg/body weight, about 5

microgram/kg/body weight to about 500 milligram/kg/body weight, etc., can be administered, based on the numbers described above.

Alimentary Compositions and Formulations. In one embodiment of the present disclosure, the inhibitors of activity and/or expression of ZnT8, or variants thereof, are formulated to be administered *via* an alimentary route. Alimentary routes include all possible routes of administration in which the composition is in direct contact with the alimentary tract. Specifically, the pharmaceutical compositions disclosed herein may be administered orally, buccally, rectally, or sublingually. As such, these compositions may be formulated with an inert diluent or with an assimilable edible carrier, or they may be enclosed in hard- or soft-shell gelatin capsule, or they may be compressed into tablets, or they may be incorporated directly with the food of the diet.

In certain embodiments, the active compounds may be incorporated with excipients and used in the form of ingestible tablets, buccal tables, troches, capsules, elixirs, suspensions, syrups, wafers, and the like (Mathiowitz et al., 1997; Hwang et al., 1998; U.S. Pat. Nos. 5,641,515; 5,580,579 and 5,792, 451, each specifically incorporated herein by reference in its entirety). The tablets, troches, pills, capsules and the like may also contain the following: a binder, such as, for example, gum tragacanth, acacia, cornstarch, gelatin or combinations thereof; an excipient, such as, for example, dicalcium phosphate, mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate or combinations thereof; a disintegrating agent, such as, for example, corn starch, potato starch, alginic acid or combinations thereof; a lubricant, such as, for example, magnesium stearate; a sweetening agent, such as, for example, sucrose, lactose, saccharin or combinations thereof; a

flavoring agent, such as, for example peppermint, oil of wintergreen, cherry flavoring, orange
flavoring, etc. When the dosage unit form is a capsule, it may contain, in addition to
materials of the above type, a liquid carrier. Various other materials may be present as
coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets,
5 pills, or capsules may be coated with shellac, sugar, or both. When the dosage form is a
capsule, it may contain, in addition to materials of the above type, carriers such as a liquid
carrier. Gelatin capsules, tablets, or pills may be enterically coated. Enteric coatings prevent
denaturation of the composition in the stomach or upper bowel where the pH is acidic. See,
e.g., U.S. Pat. No. 5,629,001. Upon reaching the small intestines, the basic pH therein
10 dissolves the coating and permits the composition to be released and absorbed by specialized
cells, *e.g.*, epithelial enterocytes and Peyer's patch M cells. A syrup or elixir may contain the
active compound sucrose as a sweetening agent methyl and propylparabens as preservatives,
a dye and flavoring, such as cherry or orange flavor. Of course, any material used in
preparing any dosage unit form should be pharmaceutically pure and substantially non-toxic
15 in the amounts employed. In addition, the active compounds may be incorporated into
sustained-release preparation and formulations.

For oral administration the compositions of the present disclosure may alternatively
be incorporated with one or more excipients in the form of a mouthwash, dentifrice, buccal
tablet, oral spray, or sublingual orally- administered formulation. For example, a mouthwash
20 may be prepared incorporating the active ingredient in the required amount in an appropriate
solvent, such as a sodium borate solution (Dobell's Solution). Alternatively, the active
ingredient may be incorporated into an oral solution such as one containing sodium borate,
glycerin and potassium bicarbonate, or dispersed in a dentifrice, or added in a therapeutically-

effective amount to a composition that may include water, binders, abrasives, flavoring agents, foaming agents, and humectants. Alternatively the compositions may be fashioned into a tablet or solution form that may be placed under the tongue or otherwise dissolved in the mouth.

5 Additional formulations which are suitable for other modes of alimentary administration include suppositories. Suppositories are solid dosage forms of various weights and shapes, usually medicated, for insertion into the rectum. After insertion, suppositories soften, melt or dissolve in the cavity fluids. In general, for suppositories, traditional carriers may include, for example, polyalkylene glycols, triglycerides or combinations thereof. In
10 certain embodiments, suppositories may be formed from mixtures containing, for example, the active ingredient in the range of about 0.5% to about 10%, and preferably about 1% to about 2%.

Parenteral Compositions and Formulations. In further embodiments, inducer of expression of
15 ZnT8 may be administered via a parenteral route. As used herein, the term “parenteral” includes routes that bypass the alimentary tract. Specifically, the pharmaceutical compositions disclosed herein may be administered for example, but not limited to intravenously, intradermally, intramuscularly, intraarterially, intrathecally, subcutaneous, or intraperitoneally U.S. Pat. Nos. 6,7537,514, 6,613,308, 5,466,468, 5,543,158; 5,641,515; and
20 5,399,363 (each specifically incorporated herein by reference in its entirety). Solutions of the active compounds as free base or pharmacologically acceptable salts may be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose. Dispersions may also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils.

Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms. The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions (U.S. Patent 5,466,468, specifically
5 incorporated herein by reference in its entirety). In all cases the form must be sterile and must be fluid to the extent that easy injectability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (*i.e.*, glycerol, propylene glycol, and
10 liquid polyethylene glycol, and the like), suitable mixtures thereof, and/or vegetable oils. Proper fluidity may be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid,
15 thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.

For parenteral administration in an aqueous solution, for example, the solution should
20 be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose. These particular aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous, and intraperitoneal administration. In this connection, sterile aqueous media that can be employed will be known to those of skill in the art in light of the

present disclosure. For example, one dosage may be dissolved in isotonic NaCl solution and either added hypodermoclysis fluid or injected at the proposed site of infusion, (see for example, "Remington's Pharmaceutical Sciences" 15th Edition, pages 1035-1038 and 1570-1580). Some variation in dosage will necessarily occur depending on the condition of the subject being treated. The person responsible for administration will, in any event, determine the appropriate dose for the individual subject. Moreover, for human administration, preparations should meet sterility, pyrogenicity, general safety and purity standards as required by FDA Office of Biologics standards.

Sterile injectable solutions are prepared by incorporating the active compounds in the required amount in the appropriate solvent with several of the other ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof. A powdered composition is combined with a liquid carrier such as, *e.g.*, water or a saline solution, with or without a stabilizing agent.

Miscellaneous Pharmaceutical Compositions and Formulations. In other preferred embodiments of the invention, the active compound inhibitor of activity and/or expression of ZnT8, or variants thereof, may be formulated for administration via various miscellaneous

routes, for example, topical (*i.e.*, transdermal) administration, mucosal administration (intranasal, vaginal, *etc.*) and/or inhalation.

Pharmaceutical compositions for topical administration may include the active compound formulated for a medicated application such as an ointment, paste, cream or
5 powder. Ointments include all oleaginous, adsorption, emulsion and water-soluble based compositions for topical application, while creams and lotions are those compositions that include an emulsion base only. Topically administered medications may contain a penetration enhancer to facilitate adsorption of the active ingredients through the skin. Suitable penetration enhancers include glycerin, alcohols, alkyl methyl sulfoxides,
10 pyrrolidones and luarocapram. Possible bases for compositions for topical application include polyethylene glycol, lanolin, cold cream and petrolatum as well as any other suitable absorption, emulsion or water-soluble ointment base. Topical preparations may also include emulsifiers, gelling agents, and antimicrobial preservatives as necessary to preserve the active ingredient and provide for a homogenous mixture. Transdermal administration of the present
15 invention may also comprise the use of a "patch". For example, the patch may supply one or more active substances at a predetermined rate and in a continuous manner over a fixed period of time.

In certain embodiments, the pharmaceutical compositions may be delivered by eye drops, intranasal sprays, inhalation, and/or other aerosol delivery vehicles. Methods for
20 delivering compositions directly to the lungs via nasal aerosol sprays has been described e.g., in U.S. Pat. Nos. 5,756,353 and 5,804,212 (each specifically incorporated herein by reference in its entirety). Likewise, the delivery of drugs using intranasal microparticle resins (Takenaga et al., 1998) and lysophosphatidyl-glycerol compounds (U.S. Pat. No. 5,725, 871,

specifically incorporated herein by reference in its entirety) are also well-known in the pharmaceutical arts. Likewise, transmucosal drug delivery in the form of a polytetrafluoroethylene support matrix is described in U.S. Pat. No. 5,780,045 (specifically incorporated herein by reference in its entirety).

5 The term aerosol refers to a colloidal system of finely divided solid or liquid particles dispersed in a liquefied or pressurized gas propellant. The typical aerosol of the present invention for inhalation will consist of a suspension of active ingredients in liquid propellant or a mixture of liquid propellant and a suitable solvent. Suitable propellants include hydrocarbons and hydrocarbon ethers. Suitable containers will vary according to the pressure requirements of the propellant. Administration of the aerosol will vary according to subject's
10 age, weight and the severity and response of the symptoms.

EXAMPLES/METHODS

Expression constructs. The human ZnT8 isoform-2 cDNA (NM_001172814.1) housed in a
15 pCMV6-entry vector (OriGene Technologies) was shuttled into a mammalian expression vector pCMV6-AC-GFP with a modified turboGFP tag appended to the C-terminus. The resulting (pZnT8-GFP) was transiently expressed in HEK293 cells by Lipofectamine transfection according to manufacturer's instructions (Thermo Fisher). The human ZnT8 cDNA insert was further subcloned into a pcDNA5/FRT/TO expression vector that used a
20 tetracycline-inducible, hybrid human cytomegalovirus (CMV)/TetO₂ promoter to control ZnT8 expression (Life technologies). A hexahistidine tag was added to the C-terminus to facilitate affinity purification. The resulting His-tagged ZnT8 expression construct (the R-form), pZnT8-His, was also mutated to generate the W-form (R325W mutation) and AA-

from (H220A, D224A double mutation) using Q5 Site-Directed Mutagenesis (New England Biolabs). All constructs were confirmed by double strand DNA sequencing.

Stable cell lines. Expression cell lines with stable integration of various ZnT8 variants were generated by co-transfection of pZnT8-His and pOG44 at 1:9 ratio into an Flp-In-T-Rex-
5 HEK293 host cell line (Life Technologies). This cell line constitutively expressed Tet repressor and contained a single integrated Flp Recombination Target (FRT) site. The expression of an Flp recombinase encoded in pOG44 mediated genomic integration of the pZnT8-His construct via homologous recombination at specific FRT sites. The integration also activated the expression of a hygromycin resistant gene, allowing antibiotic selection of
10 stable expression cell lines. Since all of the hygromycin resistant foci were isogenic, polyclonal stable cell lines were pooled and used for all experiments as described below. A separate cell line (Blk) with stable integration of the empty pcDNA5/FRT/TO vector was generated in parallel as a negative control for immunofluorescence imaging and vesicular zinc uptake experiments.

15 ZnT8 expression. Flp-In, T-REx-HEK293 cells stably expressing His-tagged ZnT8 variants were grown in Dulbecco's modified Eagle's medium supplemented with 10% tetracycline-reduced fetal bovine serum and 100 g/ml hygromycin B in 95% air, 5% carbon dioxides at 37 °C. Early-passage cells (n<10) with a >95% viability were counted (typically at 1×10^7 cells/ml), seeded at an appropriate density (see below) suited for different experiments on
20 poly-Lys coated surfaces. When cells were grown exponentially to approximately 70% confluent in monolayers, doxycycline was added to 1 µg/ml to induce ZnT8 expression. Experiments were performed 18-24 hours after expression induction.

Immunofluorescence. For visualization of His-tagged ZnT8 expression, stable expression cells were grown on coverslips with or without doxycycline induction. Cells at 50% confluence were fixed with 4% paraformaldehyde, treated with a primary mouse monoclonal antibody recognizing the C-terminal His-tag (Abcam, cat. # ab5000, dilution 1:100), followed
5 by a goat-anti-mouse secondary antibody conjugated with Alexa Fluor-594 (Thermo Fisher, cat. # A11005, dilution 1:200). Nuclei were counterstained with DAPI. For visualization of vesicular zinc accumulation, cells were grown on coverslips in glass bottom microwell dishes. Induced cells at 50% confluence were labeled by 5uM Zinpyr-1 added to the culture medium. 30 min after incubation at 37 °C, cells were washed free of excess Zinpyr-1 with
10 Dulbecco's PBS, and then exposed to 100 uM zinc added extracellularly. Cells were then imaged using a Zeiss LSM 700 inverted confocal microscope with a 63x oil objective. Alexa Fluor-594, DAPI and Zinpyr-1 fluorescence were excited by three separate laser lines (561, 405 and 488 nm), and monitored at respective emission wavelength ranges under the control of Zen software.

15 Flow cytometry. Stable expression cells were grown in 6-well cell culture plates, induced at 70% confluence, and then labeled with 5 uM Zinpyr-1 as described above. The labeled cells were washed free of excess Zinpyr-1 with Hanks' Balanced Salt Solution (HBSS) with glucose, exposed to 100 uM extracellular zinc at room temperature for 30 min. Then, cells were trypsinized, resuspended in ice-chilled HBSS at a density of 1×10^6 cells/ml, and kept on
20 ice until running through a flow cytometer. Flow cytometric analyses of vesicular zinc accumulation were performed on a MoFlo XDP cell sorter (Beckman Coulter) equipped with a 488 nm laser. Data were collected on the forward scatter, side scatter, and 525 nm fluorescence channel. More than 99% of scattering events belonged to a singlet cell

population with 98% cell viability based on propidium iodide staining analysis. Zinpyr-1 fluorescence measured from ~13,000 live cells were used to calculate the mean level of vesicular zinc accumulation for each ZnT8 variant.

Vesicular zinc uptake. An uptake buffer with a free zinc concentration ranging from 4.4 to 5 283 nM was prepared by adding 0.3-1.7 mM ZnSO₄, 1 mM ADA, 1 mM EGTA and 1 uM pyrrithione to an assay buffer (100 mM NaCl, 20 mM HEPES, 1 mM TECP, pH 7.0). The free zinc concentration in the ADA-EGTA dual buffering system was calculated using maxchelator (maxchelator.stanford.edu). Induced cells were loaded with Zinpyr-1, trypsinized, resuspended in an ice-chilled plain uptake buffer with no ZnSO₄ added. Cells 10 with the expression of each ZnT8 variant or the empty vector were counted, adjusted to a density of 4×10^6 cells/ml, and dispensed in 50- μ l aliquots to a clear-bottom 96-well microplate (Greiner bio-one). Initial Zinpyr-1 fluorescence (F_0) was recorded from the bottom on a Flexstation-3 microplate reader (Molecular dynamics), and then zinc-uptakes were initiated by adding 50 ul uptake buffers with 2x free zinc concentrations to each well. 15 The Zinpyr-1 fluorescence increases in response to various free zinc concentrations were recorded at 15 °C in the kinetic mode of Flexstation over a time course of 10 min and normalized to Zinpyr-1 loading (F_0). The fluorescence responses reached a linear phase in 2 min after the uptake temperature approached equilibrium. The rates of zinc uptake were calculated by linear regression of the Zinpyr-1 signals from 2 to 10 min. All measurements 20 were performed in 12 replicates, and fluorescence readings were obtained by averaging over 8-10 measurements that gave consistent results. Most aberrant measurements occurred in the first and last two columns of the microplate due to pipetting errors.

Purification and reconstitution. 24 hour after induction, early-passage cells (passage number < 10) at 90% confluence were scraped on ice and collected in the assay buffer supplemented with cOmplete mini EDTA free protease cocktail tablets as specified by the manufacturer (Sigma). Cell suspension was homogenized by 40 passages through a high-shear fluid processor at 120 psi (Microfluidics), and then the membrane fraction was pelleted by ultracentrifugation at 258k x g for 60 min. The membrane pellet was re-suspended in a solubilization buffer (assay buffer plus 25% glycerol). DDM was added to solubilize the membrane according to the weight of the membrane pellet at a DDM-to-membrane ratio of 1:5 (wt/wt). The membrane crude extract was cleared off debris by ultracentrifugation at 258k x g for 15 min. The supernatant was applied to Talon affinity resins (GE Healthcare) and incubated at 8 °C on a rotary shaker for 45 min. The resin was then minimally washed by solubilization buffer supplemented with 25 mM imidazole, and then the immobilized ZnT8 variant was eluted by increasing the imidazole concentration to 250 mM. The molecular identity of the eluted ZnT8 variant was validated by western blotting using two antibodies to the C-terminal His-tag (Cell signaling Technology, cat. # 2365S, catalog number, 1:1000 dilution) and to a linear peptide epitope (Proteintech, cat. #16169-I-AP, 1:500 dilution), respectively. The purity of the eluted proteins was assessed by SDS-PAGE with imperial protein staining (Thermo Scientific). Preformed liposomes with a defined lipid composition as indicated were prepared by mixing stock solutions of lipids in chloroform. The lipid mixture was dried under a stream of nitrogen gas, and traces of chloroform were removed by placing the lipids under vacuum overnight at room temperature. Dried lipids were rehydrated in a Pyrex borosilicate glass tube with assay buffer to a lipid concentration of 50 mg/ml, and then sonicated in a cup-horn sonicator at 100 W for 2 min (cycles of 10 son, 10 s off) in an

ice-chilled water bath. The resulting liposome suspension was diluted with assay buffer to a final lipid concentration of 7.5 mg/ml with DDM added at a DDM/lipids ratio of 1:1 (wt/wt). The DDM-liposome mixture was incubated at room temperature on a rotary shaker for ~3 hours until a gel-like appearance occurred. Reconstitution of ZnT8 variants took place

5 immediately after eluted from Talon resins by mixing a ZnT8 variant, or an equal volume of elution buffer, with DDM-destabilized preformed liposomes at an estimated protein-to-lipid wt/wt ratio of 1:200. The reconstitution mixture was incubated on a rotary shaker at 8 °C for 1 hr, then freshly prepared, methanol-washed polystyrene beads (Bio-Beads, SM-2, Bio-Rad) were added to the reconstitution mixture in a 60:1 wt/wt ratio to DDM. After incubation

10 overnight at 8 °C, the resulting proteoliposomes or liposomes (negative control) were separated from the detergent-soaked polystyrene beads, and pelleted by ultracentrifugation (258k x g, 2 hr). The vesicle pellets were resuspended in 0.2 ml assay buffer with 200 M FluoZin-3, subjected to 3 freeze-thaw cycles, followed by a 10 second sonication to complete dye encapsulation. The extraventricular FluoZin-3 was removed by washing vesicles with 3X25

15 ml assay buffer by three cycles of resuspending and ultracentrifugation (258k x g, 0.5 hr).

Stopped-flow kinetics. Experiments were performed at 8 °C on a SFM-3000 stopped-flow apparatus (Bio-logic). Proteoliposome or liposome samples and an assay buffer containing varying concentrations of ZnSO₄ as indicated were loaded into two separate mixing syringes. Zinc influx reactions were initiated by pushing 101 ul fresh reactants at a 1:1 ratio into a

20 mixing chamber at a flow rate of 10 ml/s. The reactants were excited at 490 nm, and emissions were monitored at 525 nm using a 10 nm bandpass cut-off filter. Kinetic traces were recorded over a time course of 10 seconds with instrument offset and gain kept constant for all the experiments. All traces were the cumulative average of 5 successive recordings.

Liposome traces were collected as baselines and subtracted from proteoliposome traces to yield net fluorescence changes ΔF . $\Delta F/\Delta F_{max}$ was obtained by normalizing ΔF to the maximum proteoliposome response elicited by an assay buffer containing 3 mM ZnSO₄ plus 2% β -OG. The initial rate of zinc influx was obtained by linear regression of data points
5 (t<1s) in the quasi-linear phase of the initial fluorescence rise. Concentration dependence data were analyzed by least squares fits of the initial transport rate to a hyperbola defined by $v_i = V_{max} \cdot M / (M + K_m)$, where M represents the zinc ion concentration, V_{max} is the maximum initial transport rate when the rate of transport approaches to a quasi-stationary state, and K_m is the Michaelis-Menten constant. Fits of experimental data were preformed using the data
10 analysis software SIGMAPLOT (SPSS Inc., Chicago, IL).

Homology modeling. The protein sequences of the R-allele of human ZnT8 isoform-2 and *E. coli* zinc transporter YiiP were aligned using MODELLER 9.16 (<https://salilab.org/modeller/>). The alignment was imported into Swiss model (<http://swissmodel.expasy.org>) to generate a homolog model of ZnT8 using the crystal
15 structure of YiiP at 2.9-angstrom resolution as a template (pdb # 3H90). The graphic representation of the resulted model was prepared using the program PyMol (Delano Scientific).

All references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference to the same extent as if each reference were individually
20 and specifically indicated to be incorporated by reference and were set forth in its entirety herein.

The use of the terms “a” and “an” and “the” and similar referents in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. The terms “comprising,” “having,” “including,” and
5 “containing” are to be construed as open-ended terms (i.e., meaning “including, but not limited to,”) unless otherwise noted. Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. All methods
10 described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., “such as”) provided herein, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed
15 element as essential to the practice of the invention.

Preferred embodiments of this invention are described herein, including the best mode known to the inventors for carrying out the invention. Variations of those preferred embodiments may become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventors expect skilled artisans to employ such variations as
20 appropriate, and the inventors intend for the invention to be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible

variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.

Claims:

1. A method of identifying a drug to treat or prevent diabetes in a subject comprising the steps of:

a. providing a proteoliposome with a zinc transporter ZnT8, or functional part thereof;

5 b. administering an agent to the proteoliposome forming a treated sample;

c. measuring the activity of the zinc transporter ZnT8 in the treated sample to obtain a first activity measurement and comparing the first activity measurement to a second activity measurement of a reference;

d. identifying the drug when the first activity measurement is lower than the second activity measurement.

2. The method of claim 1 wherein the reference is the proteoliposome with a ZnT8 transporter or variant thereof substantially free of agent.

3. The method of claim 1 wherein the activity of zinc transporter ZnT8 is the rate of zinc transport efficiency.

15 4. The method of claim 1 wherein the first measurement is from 1.5 to 5 fold lower than the second measurement.

5. The method of claim 3 wherein the rate of zinc transport efficiency is based on a V_{max}/K_m value using stopped-flow kinetics.

20 6. A method of identifying a drug to treat or prevent diabetes in a subject comprising the steps of:

a. providing a first sample that expresses a zinc transporter ZnT8, or functional part thereof;

b. administering an agent to the first sample forming a treated sample;

c. measuring the activity of the zinc transporter ZnT8 in the treated sample to obtain a first activity measurement and comparing the first activity measurement to a second activity measurement of a reference;

d. identifying the drug when the first activity measurement is lower than the second
5 activity measurement.

7. The method of claim 6 wherein the zinc transporter is the nonsynonymous variant of human ZnT8 (R325W).

8. The method of claim 6 further comprising the step of administering the drug to a subject.

10 9. The method of claim 6 wherein the first sample is in vitro human cells.

10. The method of claim 6 wherein the first sample is a biological sample obtained from a subject.

11. The method of claim 6 wherein the activity of the zinc transporter ZnT8 is measured by intracellular zinc accumulation in the sample.

15 12. The method of claim 6 wherein the activity of the zinc transporter ZnT8 is measured by a rate of zinc transport efficacy.

13. The method of claim 12 wherein the first activity measurement is from 1.5 to 5 fold lower than the second activity measurement.

14. The method of claim 13 wherein the rate of zinc transport efficiency is based on a
20 V_{max}/K_m value using stopped-flow kinetics.

15. The method of claim 6 wherein the reference is the first sample substantially free of agent.

16. The method of claim 6 wherein the zinc transporter ZnT8 is a human zinc transporter ZnT8.

17. The method of claim 6 wherein the first sample is HEK293 cells.

18. The method of claim 17 wherein the ZnT8 is a His-tagged ZnT8.

5 19. The method of claim 18 wherein the HEK293 cells stably express the His-tagged ZnT8.

20. The method of claim 6, wherein the agent is selected from the group comprising an antibody, portion of an antibody, nucleic acid, peptide, protein, chemical, or combination thereof.

10 21. The method of claim 20, wherein the agent is a chemical.

22. A pharmaceutical composition comprising the drug of any one of claims 1-21, salt, solvate, or stereoisomer thereof.

23. The method of claim 22 wherein the drug is a lipid.

15 24. The method of claim 23 wherein the lipid is selected from the group consisting of lysophosphatidylcholines, cholesterol, or a combination of.

25. A method of inhibiting ZnT8 activity in pancreas cells of a subject comprising administering to the subject an effective amount of the drug of any one of claims 1-24, salt, solvate, or stereoisomer thereof.

20 26. The method of claim 25 wherein the ZnT8 activity is measured in a sample taken from the subject before and after the subject is administered the drug by determining the rate of zinc transport efficiency in the sample.

27. The method of claim 26 wherein the rate of zinc transport efficiency after the subject is administered the drug is from 1.5 to 5 fold lower than before the subject was administered the drug.

28. The method of claim 27 wherein the rate of zinc transport efficiency is based on a
5 V_{max}/K_m value using stopped-flow kinetics.

29. A method of treating or preventing diabetes in a subject comprising administering to the subject an effective amount of the drug, salt, solvate, or stereoisomer of any one of the claims 1-24.

30. A method of purifying a zinc transporter ZnT8 comprising the steps of:
10 providing a crude preparation of a zinc transporter ZnT8 comprising proteins other than the zinc transporter ZnT8;
reconstituting the crude preparation of the zinc transporter ZnT8 in a liposome forming a transporter proteoliposome comprising the ZnT8 in a solution;
separating the solution from the transporter proteoliposome; and
15 forming a purified zinc transporter ZnT8.

31. The method of claim 30 wherein the liposome comprises a lipid selected from the group consisting of anionic phospholipids, non-bilayer phospholipids, cholesterol, or a combination thereof.

32. The method of claim 30 wherein the liposome comprises a lipid selected from the
20 group consisting of phosphatidylinositol (PI), phosphatidylserine (PS), lysophosphatidylcholine (LPC), cholesterol, or a combination thereof.

33. The method of claim 31 wherein the crude preparation of zinc transporter ZnT8 is reconstituted in a liposome to maintain the activity of zinc transporter ZnT8 during the separation step.

34. The method of claim 30 wherein the separation occurs by centrifugation.

5 35. The method of claim 30 wherein the purified Zinc transporter ZnT8 has a V_{max} greater than 4.

36. The method of claim 30 wherein the purified Zinc transporter ZnT8 has a V_{max} greater than 5.

10 37. The method of claim 30 wherein the purified Zinc transporter ZnT8 has a V_{max} greater than 6.

38. The method of claim 30 wherein the purified zinc transporter ZnT8 is in the R-form, the W-form, or a combination thereof.

39. The method of claim 30 wherein the crude preparation of zinc transporter ZnT8 is a product of affinity purification.

15 40. The method of claim 39 wherein the affinity purification comprises metal affinity resins.

41. The method of claim 30 comprising the step of detecting anti-ZnT8 autoantibodies in a subject using the purified zinc transporter ZnT8.

20 42. The method of claim 41 wherein detection of anti-ZnT8 autoantibodies in a subject is a diagnosis of type -1 diabetes.

43. The method of claim 30 comprising the step of generating anti-ZnT8 mAbs.

44. The method of claim 43, wherein the anti-ZnT8 mAbs are humanized anti-ZnT8 mAbs.

45. The method of claim 44, comprising the step of performing diagnostic beta-cell imaging using the humanized anti-ZnT8 mAbs.

46. The method of claim 44 comprising the step of performing a mAb-based therapeutic ZnT8 inhibitors using the humanized anti-ZnT8 mAbs.

5

10

1/6




FIG. 1A




FIG. 1B




FIG. 1C




FIG. 1D




FIG. 2A




FIG. 2B




FIG. 2C




FIG. 3A






FIG. 3B




FIG 4




FIG. 5




FIG. 6

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 2017/029250

A. CLASSIFICATION OF SUBJECT MATTER		
<i>A61K 9/127 (2006.01)</i> <i>G01N 33/68 (2006.01)</i> <i>A61P 3/10 (2006.01)</i>		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols)		
A61K 9/127, G01N 33/52-33/68, A61P 3/10		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)		
PatSearch (RUPTO internal), USPTO, PAJ, Esp@cenet, DWPI, EAPATIS, PATENTSCOPE		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 2009/0191574 A1 (PRESIDENT AND FELLOWS OF HARVARD) 30.07.2009	1-46
A	WO 2012/062697 A1 (NOVARTIS AG et al.) 18.05.2012	1-46
A	US 2012/0238572 A1 (REGIMMUNE CORPORATION) 27.08.2015	1-46
A	DAVIDSON Howard W. et al. Zinc transporter 8 (ZNT8) and beta cell function. Trends Endocrinol Metab. 2014 August; 25(8): 415-424	1-46
A	YI Bo et al. Different role of zinc transporter 8 between type 1 diabetes mellitus and type 2 diabetes mellitus. J Diabetes Investig 2016; 7: 459-465	1-46
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents:	“T”	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
“A” document defining the general state of the art which is not considered to be of particular relevance	“X”	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
“E” earlier document but published on or after the international filing date	“Y”	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
“L” document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	“&”	document member of the same patent family
“O” document referring to an oral disclosure, use, exhibition or other means		
“P” document published prior to the international filing date but later than the priority date claimed		
Date of the actual completion of the international search	Date of mailing of the international search report	
28 July 2017 (28.07.2017)	17 August 2017 (17.08.2017)	
Name and mailing address of the ISA/RU: Federal Institute of Industrial Property, Berezhkovskaya nab., 30-1, Moscow, G-59, GSP-3, Russia, 125993 Facsimile No: (8-495) 531-63-18, (8-499) 243-33-37	Authorized officer E. Vinogradova Telephone No. 8-499-240-25-91	